Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 10/10

vs
industry
vs
history
Cash to Debt 273.71
OPHLY's Cash to Debt is ranked higher than
81% of the 773 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.62 vs. OPHLY: 273.71 )
OPHLY' s 10-Year Cash to Debt Range
Min: 268.88   Max: 11991.36
Current: 273.71

268.88
11991.36
Equity to Asset 0.93
OPHLY's Equity to Asset is ranked higher than
97% of the 714 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.61 vs. OPHLY: 0.93 )
OPHLY' s 10-Year Equity to Asset Range
Min: 0.91   Max: 0.94
Current: 0.93

0.91
0.94
F-Score: 5
Z-Score: 15.07
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Revenue Growth (%) 2.60
OPHLY's Revenue Growth (%) is ranked higher than
64% of the 629 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.10 vs. OPHLY: 2.60 )
OPHLY' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 3.5
Current: 2.6

0
3.5
EBITDA Growth (%) -4.00
OPHLY's EBITDA Growth (%) is ranked higher than
62% of the 594 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.60 vs. OPHLY: -4.00 )
OPHLY' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 1
Current: -4

0
1
EPS Growth (%) -100.00
OPHLY's EPS Growth (%) is ranked lower than
55% of the 595 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.00 vs. OPHLY: -100.00 )
OPHLY' s 10-Year EPS Growth (%) Range
Min: 0   Max: 2.1
Current: -100

0
2.1
» OPHLY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

OPHLY Guru Trades in

OPHLY Guru Trades in

OPHLY Guru Trades in

Q3 2012

OPHLY Guru Trades in Q3 2012

Vanguard Health Care Fund 960,000 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with OPHLY



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 30.10
OPHLY's P/E(ttm) is ranked higher than
80% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 41.40 vs. OPHLY: 30.10 )
OPHLY' s 10-Year P/E(ttm) Range
Min: 16.92   Max: 48.47
Current: 30.1

16.92
48.47
P/B 1.60
OPHLY's P/B is ranked higher than
86% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.22 vs. OPHLY: 1.60 )
OPHLY' s 10-Year P/B Range
Min: 0.93   Max: 1.74
Current: 1.6

0.93
1.74
P/S 6.54
OPHLY's P/S is ranked higher than
63% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.55 vs. OPHLY: 6.54 )
OPHLY' s 10-Year P/S Range
Min: 2.89   Max: 11.92
Current: 6.54

2.89
11.92
PFCF 46.80
OPHLY's PFCF is ranked higher than
85% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. OPHLY: 46.80 )
OPHLY' s 10-Year PFCF Range
Min: 15.17   Max: 152.05
Current: 46.8

15.17
152.05
EV-to-EBIT 22.88
OPHLY's EV-to-EBIT is ranked higher than
81% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 32.81 vs. OPHLY: 22.88 )
OPHLY' s 10-Year EV-to-EBIT Range
Min: 7   Max: 23.7
Current: 22.88

7
23.7
PEG 429.80
OPHLY's PEG is ranked higher than
68% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 367.50 vs. OPHLY: 429.80 )
OPHLY' s 10-Year PEG Range
Min: 0   Max: 439.6
Current: 429.8

0
439.6
Current Ratio 7.03
OPHLY's Current Ratio is ranked higher than
91% of the 761 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.31 vs. OPHLY: 7.03 )
OPHLY' s 10-Year Current Ratio Range
Min: 6.52   Max: 9.15
Current: 7.03

6.52
9.15
Quick Ratio 6.16
OPHLY's Quick Ratio is ranked higher than
91% of the 761 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.68 vs. OPHLY: 6.16 )
OPHLY' s 10-Year Quick Ratio Range
Min: 5.83   Max: 8.47
Current: 6.16

5.83
8.47

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 0.87
OPHLY's Dividend Yield is ranked higher than
65% of the 453 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.37 vs. OPHLY: 0.87 )
OPHLY' s 10-Year Dividend Yield Range
Min: 2.16   Max: 4.24
Current: 0.87

2.16
4.24
Dividend Payout 0.39
OPHLY's Dividend Payout is ranked higher than
51% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. OPHLY: 0.39 )
OPHLY' s 10-Year Dividend Payout Range
Min: 1.28   Max: 231.43
Current: 0.39

1.28
231.43
Dividend growth (3y) -100.00
OPHLY's Dividend growth (3y) is ranked higher than
52% of the 317 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.50 vs. OPHLY: -100.00 )
OPHLY' s 10-Year Dividend growth (3y) Range
Min: 0   Max: -100
Current: -100

Yield on cost (5-Year) 0.90
OPHLY's Yield on cost (5-Year) is ranked higher than
74% of the 461 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.39 vs. OPHLY: 0.90 )
OPHLY' s 10-Year Yield on cost (5-Year) Range
Min: 2.16   Max: 4.24
Current: 0.9

2.16
4.24
Share Buyback Rate 100.00
OPHLY's Share Buyback Rate is ranked higher than
99% of the 556 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -1.70 vs. OPHLY: 100.00 )
OPHLY' s 10-Year Share Buyback Rate Range
Min: 0   Max: 0.8
Current: 100

0
0.8

Valuation & Return

vs
industry
vs
history
Price/Net Cash 217.10
OPHLY's Price/Net Cash is ranked lower than
57% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. OPHLY: 217.10 )
OPHLY' s 10-Year Price/Net Cash Range
Min: 3.67   Max: 8.45
Current: 217.1

3.67
8.45
Price/Net Current Asset Value 1.80
OPHLY's Price/Net Current Asset Value is ranked higher than
66% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. OPHLY: 1.80 )
OPHLY' s 10-Year Price/Net Current Asset Value Range
Min: 3.45   Max: 7.36
Current: 1.8

3.45
7.36
Price/Tangible Book 0.40
OPHLY's Price/Tangible Book is ranked lower than
59% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.40 vs. OPHLY: 0.40 )
OPHLY' s 10-Year Price/Tangible Book Range
Min: 0.98   Max: 1.7
Current: 0.4

0.98
1.7
Price/Median PS Value 1.90
OPHLY's Price/Median PS Value is ranked lower than
59% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.20 vs. OPHLY: 1.90 )
OPHLY' s 10-Year Price/Median PS Value Range
Min: 0.91   Max: 3.36
Current: 1.9

0.91
3.36
Price/Graham Number 0.40
OPHLY's Price/Graham Number is ranked lower than
53% of the 806 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.60 vs. OPHLY: 0.40 )
OPHLY' s 10-Year Price/Graham Number Range
Min: 0.82   Max: 1.59
Current: 0.4

0.82
1.59
Earnings Yield (Greenblatt) 4.40
OPHLY's Earnings Yield (Greenblatt) is ranked higher than
71% of the 624 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.90 vs. OPHLY: 4.40 )
OPHLY' s 10-Year Earnings Yield (Greenblatt) Range
Min: 4.2   Max: 14.3
Current: 4.4

4.2
14.3

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare: » details
Traded in other countries:4528.Japan, 4528.Japan
Ono Pharmaceutical Co., Ltd.. is primarily engaged in the manufacture and sale of pharmaceuticals. The Company offers oral medication for the treatment of bronchial asthma, disturbances of peripheral circulation etc.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide